A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

This is a Study to Evaluate the Efficacy and Safety of Multiple Combination Therapies with FWD1802 in Subjects with ER-positive/HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer

Trial Details

NCT ID
NCT07002177
Phase
PHASE1 / PHASE2
Sponsor
Forward Pharmaceuticals Co., Ltd.
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • FWD1802
  • Palbociclib 125mg
  • Ribociclib 200Mg Oral Tablet
  • Abemaciclib 150 MG
  • Everolimus 10 mg
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Subjects consent to provide blood samples for centralized laboratory testing of ESR1 mutation status and other biomarkers.
  • Histologically or cytologically confirmed ER-positive/HER2-negative locally advanced or metastatic breast cancer
  • Subjects must meet at least one of the following criteria: postmenopausal or prior bilateral oophorectomy, or postmenopausal or Premenopausal/perim…
  • Prior Therapy Requirements:Subjects must meet all of the following criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →